+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serotonin antagonists: a new class of antiemetic agents



Serotonin antagonists: a new class of antiemetic agents



Journal of the National Cancer Institute 83(9): 613-620



Despite a number of significant advances over the past decade, prevention and treatment of chemotherapy-induced emesis remain formidable problems, particularly with cisplatin-containing regimens. Nearly one third of patients receiving high-dose cisplatin still experience substantial emesis despite the best available conventional antiemetics, and the toxic effects of these agents remain quite troublesome. In recent years, a new class of agents, the serotonin antagonists, has been identified. These agents hold promise for clinical utility in a wide range of areas. Selective antagonists of the serotonin (5-hydroxytryptamine) type 3 (5-HT3) receptor have proven in early clinical trials to be potent antiemetic agents in patients receiving cytotoxic chemotherapy, with efficacy comparable to or superior to that of conventional antiemetics. Toxic effects to date with the 5-HT3 receptor antagonists have been modest. The current state of knowledge with respect to these agents as antiemetics for patients receiving cytotoxic chemotherapy is summarized.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 033355858

Download citation: RISBibTeXText

PMID: 1850806

DOI: 10.1093/jnci/83.9.613


Related references

Potent antiemetic effects of the new serotonin antagonists. Western Journal of Medicine 156(1): 67-67, 1992

Antiemetic effects of ad 5370 a novel serotonin 5 ht 3 receptor antagonists. European Journal of Pharmacology 183(4): 1214-1215, 1990

The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications. Drugs 53(1): 20-39, 1997

Enhancing the effectiveness of the specific serotonin antagonists: combination antiemetic therapy with dexamethasone. Cancer (Philadelphia) 72(11 SUPPL.): 3436-3442, 1993

Type-3 serotonin receptor blockaders (5-HT3)--a new class of antiemetic preparations. Eksperimental'naia i Klinicheskaia Farmakologiia 57(4): 72-75, 1994

Third type serotonin receptor blockers (5-HT-3) as a new class of antiemetic drugs. Eksperimental'naya i Klinicheskaya Farmakologiya 57(4): 72-75, 1994

A new class of antiemetic agents on the horizon. Clinical Journal of Oncology Nursing 6(2): 103-104, 2002

Ondansetron--the first of a new class of antiemetic agents. Clinical Pharmacy 10(6): 430-446, 1991

Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 47(5): 319-322, 2000

Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy. Annals of PharmacoTherapy 46(12): 1637-1644, 2013

Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents. Medicinal Research Reviews 19(1): 25-73, 1999

Covalent complexes of albumin with serotonin ketanserin and lysergic acid a new class of serotonin specific human anti platelet aggregation agents. FASEB Journal 3(4): A1050, 1989

Antiemetic placebo: reduce adverse drug interactions between chemotherapeutic agents and antiemetic drugs in cancer patients. Medical Hypotheses 70(3): 551-555, 2007

Serotonin receptor antagonists: a novel class of anti-emetics. Netherlands Journal of Medicine 37(1-2): 1-3, 1990